Story
Silence Therapeutics Stock Surges 16% Ahead of Key Divesiran Trial Data

Shares of Silence Therapeutics (NASDAQ: SLN) surged in pre-market trading Monday as investors anticipated the release of crucial mid-stage trial data for its lead drug candidate, divesiran. The biotechnology company's stock climbed 16.2% ahead of a scheduled conference call to discuss the results.
Key Catalyst: Divesiran Data Readout
Silence Therapeutics announced over the weekend it would hold a conference call and webcast at 8:00 a.m. EDT on Monday to discuss topline results from its Phase 2 SANRECO trial. The trial evaluates divesiran, an siRNA therapeutic, for the treatment of polycythemia vera (PV), a rare blood disorder.
Management has previously described this data release as a "defining milestone" for the company. The event is considered the most significant near-term catalyst, heightening investor focus on the outcome of the clinical study.
High Expectations for SANRECO Trial
Investor optimism heading into the data release was underpinned by strong results from the drug's Phase 1 trial. That earlier study showed that the number of required phlebotomy procedures (blood withdrawals) for participants fell from 80 in the six months prior to treatment to just 5 during the active treatment period.
AdThe Phase 2 SANRECO study is a 48-patient, randomized, double-blind, placebo-controlled trial. Its primary endpoint measures the proportion of patients who can maintain a hematocrit level below 45% without needing phlebotomies between weeks 18 and 36 of the study.
Market Context and Regulatory Status
Divesiran's potential has already been recognized by regulators, with the U.S. Food and Drug Administration granting it both Fast Track and Orphan Drug designations. These designations can help expedite the drug's development and review process.
The significant stock movement was company-specific, occurring against a relatively neutral market backdrop where the S&P 500 and NASDAQ saw only minor gains. The surge positions the data readout as a potential transformative event for the clinical-stage biotechnology firm.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.